CD66C
1 article · search the full text for this term
-
An Evaluative Comparison of CD123 and CD66c as Biomarkers to Detect Minimal Residual Disease in B-Cell Acute Lymphoblastic Leukemia
Abstract: Background: B-cell Acute Lymphoblastic Leukemia (B-ALL) often shows lineage heterogeneity with lymphoid cells expressing myeloid markers. Minimal Residual Disease (MRD) refers to the small number of cancer cells that may remain in a patient's body after treatment and that are undetectable by standard diagnostic methods. In diseases like B-cell Acute Lymphoblastic Leukemia (B-ALL), MRD is a critical prognostic indicator, as its presence can signal a higher risk of relapse. In …
Published in Research and Reviews : A Journal of Medical Science and Technology · Vol. 13, Issue 3, 2024 · pp. 7–12 Read article